secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0000950170-25-040755
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio reports FY2024 net loss $83.6M; cash $163.1M; KRRO-110 interim readout H2 2025
--------------------------------------------------------------------------------

- Net loss $83.6M (vs $81.2M in 2023); R&D expenses $63.6M; G&A $30.5M.
- Cash, cash equivalents $163.1M; runway into H2 2026 expected to fund KRRO-110 trial.
- KRRO-110 Phase 1/2a REWRITE trial: completed dosing first two cohorts; no SAEs; interim data H2 2025.
- FDA granted Orphan Drug Designation for KRRO-110 for AATD.
- Collaboration revenue $2.3M from Novo Nordisk partnership; second development candidate expected end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000095017025040755/0000950170-25-040755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000095017025040755/krro-20250318.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-040755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer